Mucopolysaccharidosis type I

What is Mucopolysaccharidosis type I?

Mucopolysaccharidosis type I (MPS I), also known as Hurler syndrome, is a rare inherited metabolic disorder caused by deficiency of the enzyme alpha-L-iduronidase (IDUA). This enzyme deficiency leads to the accumulation of complex sugar molecules called glycosaminoglycans in cells throughout the body, causing progressive damage to organs and tissues. MPS I affects approximately 1 in 100,000 births worldwide and follows an autosomal recessive inheritance pattern. The condition is part of a group of lysosomal storage disorders that can cause significant physical and developmental challenges if left untreated.

Key statistics

Symptoms

Common symptoms include: Coarse facial features, corneal clouding, skeletal abnormalities (dysostosis multiplex), enlarged liver and spleen (organomegaly), heart valve disease, hearing loss, respiratory problems, joint stiffness, short stature, developmental delays.

The symptoms of MPS I vary significantly depending on the severity of enzyme deficiency. In severe forms (historically called Hurler syndrome), symptoms typically appear in the first year of life and include distinctive coarse facial features with a prominent forehead, thick lips, and enlarged tongue. Corneal clouding develops early, leading to vision problems. Skeletal abnormalities known as dysostosis multiplex cause characteristic bone deformities, including an enlarged skull, thickened ribs, and spine curvature.

Organomegaly, particularly enlargement of the liver and spleen, is common and can cause abdominal distension. Heart valve disease frequently develops, leading to breathing difficulties and reduced exercise tolerance. Progressive hearing loss occurs due to fluid accumulation and structural changes in the ear. Joint stiffness and contractures limit mobility and daily activities.

Submit Your Paper

In milder forms (historically called Scheie syndrome or Hurler-Scheie syndrome), symptoms may not appear until school age or adolescence, with normal intelligence but similar physical manifestations that progress more slowly.

Causes and risk factors

MPS I is caused by mutations in the IDUA gene, which provides instructions for producing the alpha-L-iduronidase enzyme. This enzyme is essential for breaking down glycosaminoglycans (dermatan sulfate and heparan sulfate) within cellular structures called lysosomes. When the enzyme is deficient or absent, these complex molecules accumulate in cells throughout the body, particularly affecting the brain, heart, bones, joints, and other organs.

The condition follows an autosomal recessive inheritance pattern, meaning both parents must be carriers (having one mutated copy of the gene) for a child to be affected. Each pregnancy between two carriers has a 25% chance of producing an affected child, a 50% chance of producing a carrier, and a 25% chance of producing a child with two normal gene copies.

Risk factors include having parents who are carriers of IDUA gene mutations, consanguineous marriages (marriages between relatives), and certain ethnic backgrounds where specific mutations may be more common.

Prevention

There is no way to prevent MPS I as it is an inherited genetic condition. However, genetic counseling and testing can help families understand their risk and make informed reproductive decisions. Carrier testing can identify individuals who carry one copy of a mutated IDUA gene, which is particularly important for family members of affected individuals or those from high-risk populations.

Prenatal testing through chorionic villus sampling or amniocentesis can diagnose MPS I during pregnancy. Preimplantation genetic diagnosis (PGD) is also available for couples using in vitro fertilization. Newborn screening programs in some regions can detect MPS I early, allowing for prompt treatment initiation before irreversible damage occurs.

Complications

Without treatment, MPS I can lead to severe, life-threatening complications. Progressive heart valve disease can cause heart failure and significantly reduce life expectancy. Airway obstruction due to tissue thickening and enlarged organs can cause respiratory failure. Spinal cord compression from bone abnormalities can lead to paralysis.

Hydrocephalus (fluid accumulation in the brain) can cause increased intracranial pressure and further neurological damage. Progressive corneal clouding can result in severe vision impairment or blindness. Hearing loss can become profound, affecting communication and development. Joint contractures and bone deformities can severely limit mobility and independence.

In severe forms, without treatment, life expectancy is typically limited to the first decade of life. Even with treatment, some complications may be irreversible if significant damage has already occurred before therapy initiation.

Diagnosis

Diagnosis of MPS I involves multiple approaches. Initial suspicion often arises from clinical features, particularly the characteristic coarse facial features, corneal clouding, and skeletal abnormalities visible on X-rays. Urine glycosaminoglycan analysis shows elevated levels of dermatan and heparan sulfate.

Definitive diagnosis requires measuring alpha-L-iduronidase enzyme activity in blood, dried blood spots, or cultured skin fibroblasts. Enzyme activity is typically less than 10% of normal levels in affected individuals. Genetic testing to identify specific IDUA gene mutations confirms the diagnosis and can guide treatment decisions and family counseling.

Additional diagnostic tests include echocardiography to assess heart valve function, ophthalmologic examination to evaluate corneal clouding, hearing tests, and imaging studies including skeletal surveys and brain MRI to assess the extent of organ involvement.

Treatment

Treatment options for MPS I include enzyme replacement therapy and hematopoietic stem cell transplantation (HSCT). Laronidase is an FDA-approved enzyme replacement therapy administered intravenously every week. This recombinant human alpha-L-iduronidase helps reduce glycosaminoglycan accumulation and can improve many symptoms, particularly organomegaly and respiratory function.

HSCT, typically using bone marrow or umbilical cord blood, can provide a long-term source of the missing enzyme and may be particularly beneficial for preserving cognitive function in severe forms when performed early in life. The procedure carries significant risks but can be life-saving.

Supportive therapies are crucial and include physical therapy to maintain joint mobility, respiratory support, hearing aids or cochlear implants for hearing loss, and surgical interventions for complications such as carpal tunnel syndrome, hernias, or heart valve disease. Regular monitoring by a multidisciplinary team is essential for optimal management.

Prognosis

The prognosis for MPS I has improved significantly with early diagnosis and treatment. Without treatment, severe forms typically result in death within the first decade due to cardiovascular and respiratory complications. Milder forms may have normal lifespans but with progressive disability.

With appropriate treatment, particularly when started early, many individuals can experience improved quality of life and extended survival. Enzyme replacement therapy can reduce organ enlargement, improve respiratory function, and increase exercise tolerance. HSCT performed before age 2 years in severe forms can preserve cognitive function and significantly improve long-term outcomes.

However, some complications such as skeletal abnormalities and corneal clouding may not be fully reversible. Early intervention remains crucial for optimizing outcomes, emphasizing the importance of newborn screening and prompt treatment initiation.

Quality of life

Living with MPS I requires ongoing medical care and adaptations, but many individuals can lead fulfilling lives with appropriate support. Regular physical therapy helps maintain mobility and joint function. Adaptive equipment may be needed for daily activities, and home modifications can improve accessibility.

Educational support is often necessary, ranging from hearing accommodations to specialized learning programs depending on cognitive involvement. Many individuals with milder forms attend mainstream schools and pursue higher education or employment. Maintaining social connections and participating in age-appropriate activities is important for psychological well-being.

Families benefit from connecting with support groups and patient organizations that provide practical advice, emotional support, and advocacy resources. Mental health support may be helpful for coping with the challenges of a chronic condition.

Pregnancy and fertility

Fertility is generally not directly affected by MPS I, though physical complications may impact pregnancy. Women with MPS I require specialized obstetric care due to potential airway difficulties, heart problems, and skeletal abnormalities that could complicate delivery.

Enzyme replacement therapy appears to be relatively safe during pregnancy, though careful monitoring is essential. Genetic counseling is crucial for affected individuals and carriers to understand inheritance risks and reproductive options. Each pregnancy of an affected individual with an unaffected partner has a 100% chance of producing a carrier child.

Children

Early diagnosis in children is critical for optimal outcomes. Parents should monitor for developmental delays, hearing problems, frequent respiratory infections, and characteristic physical features. Regular pediatric follow-up with MPS-experienced specialists is essential.

Educational planning should begin early, incorporating hearing and vision accommodations as needed. Physical therapy and occupational therapy help maintain function and independence. Psychological support helps children and families cope with the challenges of living with a chronic condition.

When to see a doctor

Immediate medical attention is needed for signs of serious complications including severe breathing difficulties, chest pain, signs of heart failure (such as swelling or extreme fatigue), severe headaches that could indicate increased intracranial pressure, or neurological changes such as weakness or loss of coordination.

Routine care should include regular monitoring for disease progression and treatment effectiveness. Any new symptoms or worsening of existing symptoms should be evaluated promptly by the healthcare team.

Regional context

Specific prevalence data for MPS I in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries is limited. Some populations may have founder effects or consanguineous marriage patterns that could affect local prevalence. Healthcare infrastructure for rare disease diagnosis and treatment varies significantly across the region.

We invite healthcare professionals and researchers from these regions to contribute their experiences and data to the Global Medical Journal to improve understanding of MPS I prevalence and management in diverse populations.

Research and clinical trials

Current research focuses on improving enzyme replacement therapies, developing gene therapies, and investigating substrate reduction therapies. Novel approaches include intrathecal enzyme delivery to better reach the central nervous system and next-generation enzyme replacements with improved tissue distribution.

Gene therapy trials using viral vectors to deliver functional IDUA genes show promise for providing long-term enzyme production. Substrate reduction therapy aims to decrease glycosaminoglycan production rather than just replacing the missing enzyme.

Patients can search for current clinical trials at ClinicalTrials.gov using the search term “mucopolysaccharidosis type I” or “MPS I.”

Frequently asked questions

Is MPS I the same as Hurler syndrome?

Yes, Hurler syndrome is the historical name for the severe form of MPS I. All forms of MPS I are now considered part of a spectrum based on the same enzyme deficiency.

Can MPS I be cured?

While there is no definitive cure, treatments like enzyme replacement therapy and stem cell transplantation can significantly improve symptoms and outcomes, especially when started early.

Will my other children have MPS I if one child is affected?

If both parents are carriers, each subsequent pregnancy has a 25% chance of being affected. Genetic counseling can provide personalized risk assessment.

How long do people with MPS I live?

Life expectancy varies greatly depending on severity and treatment. With early, appropriate treatment, many individuals can live into adulthood with good quality of life.

Can adults develop MPS I?

MPS I is present from birth, but milder forms may not be diagnosed until adulthood when symptoms become apparent or progress significantly.

Support and resources

• National MPS Society – Comprehensive patient advocacy and support organization
• Orphanet – European database of rare diseases
• National Organization for Rare Disorders (NORD)
• EURORDIS – European rare disease organization
• World Health Organization Rare Diseases

Related conditions

• Mucopolysaccharidosis type II (Hunter syndrome)
• Mucopolysaccharidosis type III (Sanfilippo syndrome)
• Gaucher disease
• Fabry disease
• Pompe disease

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.